Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2023

Earnings data Q2 2023

Bank of Montreal - ZC SP ETN REDEEM 25/03/2039 USD 50 - Ser E SMTN

Celsius Holdings

Eldorado Gold

Enphase Energy

Direxion Daily Financial Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

McDonald's

Merck

Northern Oil and Gas

ProShares Ultra VIX Short-Term Futures ETF

Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear funds in the Active ETF with over 17% gains this week. SUP peaked at +20.9% for members.

MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Al Sandrock - Chief Executive Officer Todd Carter - Chief Scientific Officer Pete Pfreundschuh - Chief Financial Officer Allen Nunnally - Chief Business Officer Conference Call Participants Jack Allen - Baird Joon Lee - Truist Dane Leone - Raymond James Yun Zhong - BTIG Laura Chico - Wedbush Yanan Zhu - Wells Fargo Jay Olson - Oppenheimer Operator Good morning and welcome to Voyager Therapeutics 2022 Fourth Quarter and Year End Conference Call. All participants are now in listen-only mode.

Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™  novel capsid platform through transactions with Pfizer and Novartis -

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report fourth quarter and full year 2023 financial and operating results before the market opens on Tuesday, March 7, 2023. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

Las Vegas Sands

nCino, Inc.

Some of the notable companies to have witnessed solid earnings acceleration as of now are Las Vegas Sands (LVS), Voyager Therapeutics (VYGR) & nCino (NCNO).

3 Best Stocks to Invest in for Remarkable Earnings Acceleration

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees' entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager's Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award to each employee became effective on January 23, 2023, and the restricted stock unit award to each employee is scheduled to become effective on April 1, 2023.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors are taking profits on this red-hot stock this week.

Why Voyager Therapeutics Stock Is Sinking This Week

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Voyager Therapeutics (VYGR)'s Technical Outlook is Bright After Key Golden Cross

In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle some of the most difficult to treat neurological conditions like Alzheimer's disease, ALS, and Parkinson's.

Voyager: Recent Neurocrine Deal Signals More Upside

Neurocrine Biosciences

Voyager Therapeutics Inc (NASDAQ:VYGR) shares have jumped on the news that the biotechnology company has entered into a strategic collaboration with Neurocrine Biosciences (NASDAQ:NBIX) Inc to advance multiple gene therapies for the treatment of neurological diseases. The company's stock was up 15.7% at US$8.05 just before noon on Monday, while Neurocrine shares had shed 9.3% to US$111.62.

Voyager Therapeutics stock soars, analysts raise price target on new collaboration with Neurocrine Biosciences to advance its gene therapies

Why is Voyager Therapeutics (NASDAQ: VYGR ) stock today up while Neurocrine Biosciences (NASDAQ: NBIX ) is down? Evidently, today's movement is because of a deal between the two biotechnology businesses to develop and commercialize gene therapies for the treatment of neurological diseases.

Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal

Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, +0.06% to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson's disease. Neurocrine will make a $175 million upfront payment, including a $39 million equity investment, with up to $1.5 billion in potential milestones.

Voyager, Neurocrine ink gene-therapy deal

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following Phase 1 readout -

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

Boeing

Caterpillar

Chevron

JPMorgan Chase & Co

Sensus Healthcare

Visa

Two new Breakout Stocks for Week 2 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. Momentum Gauge trading signal turned positive this week and new portfolios are all positive with strong gains to start the new year.

MDA Breakout Stocks Week 2 - January 2023: High-Frequency Gainers To Give You An Edge

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc.

Voyager Therapeutics Appoints Grace E. Colón, Ph.D.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter Pfreundschuh - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird Philip Nadeau - Cowen and Company Laura Chico - Wedbush Yung Zhong - BTIG Dane Leone - Raymond James Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call.

Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

- Voyager's TRACER TM capsid platform validated by Pfizer option exercise -

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?

- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 -

News for Voyager Therapeutics Stock (VYGR)